开展临床实验规模最大的目前要数Moderna。Moderna在募集充足的资金之后便与外部合作伙伴开始了50多个药物研发项目,并成立了三家附属公司:Onkaido,Valera和Elpidera。开始大规模的在肿瘤,传染病,罕见病,心血管疾病领域展开临床研究。
总而言之,作为一个新型的制药领域,mRNA具有相当可观的前景,并且竞争也相当激烈,目前除了Moderna之外,CureVac,BioNTech,Arcturus等目前吸引了众多投资的专mRNA生物技术公司都在积极开展临床研究。虽然各大mRNA公司目前并没有公布太多的临床数据,但是一旦mRNA在人体实验中取得突破,那么mRNA必将会轰动整个制药领域,为多种罕见病,感染性疾病以及癌症患者带来新的治疗希望。
参考资料:
1.Bahl K, Senn J J, Yuzhakov O, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses[J]. Molecular Therapy, 2017.
2.Richner J M, Himansu S, Dowd K A, et al. Modified mRNA vaccines protect against Zika virus infection[J]. Cell, 2017, 168(6): 1114-1125. e10.
3.Pardi N, Hogan M J, Pelc R S, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination[J]. Nature, 2017, 543(7644): 248-251.
4.https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/
5.http://www.xconomy.com/boston/2015/01/05/with-massive-venture-round-moderna-has-450m-reasons-to-stay-private/?single_page=true
6.http://www.xconomy.com/boston/2016/08/29/filing-moderna-blowing-past-record-450m-round-with-new-600m-raise/#
7.http://www.sciencemag.org/news/2017/02/mysterious-2-billion-biotech-revealing-secrets-behind-its-new-drugs-and-vaccines
8.Wolff J A, Malone R W, Williams P, et al. Direct gene transfer into mouse muscle in vivo[J]. Science, 1990, 247(4949): 1465-1469.
9.Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs[J]. Nature reviews Drug discovery, 2014, 13(10): 759-780.
10.Karikó K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23(2): 165-175.